Thirty years of medical surveillance in perfluooctanoic acid production workers

Journal of Occupational and Environmental Medicine

Volumn 51, Issue 3, 2009, Pages 364-372

  Costa, Giovanni ^a   Sartori, Samantha ^a   Consonni, Dario ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PERFLUOROOCTANOIC ACID; URIC ACID;

ADULT; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HEALTH HAZARD; HEALTH SURVEY; HUMAN; HUMAN EXPERIMENT; INDUSTRIAL WORKER; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PERIODIC MEDICAL EXAMINATION; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; URIC ACID BLOOD LEVEL;

EID: 63449102135     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3181965d80     Document Type: Article

References (53)

1. Kennedy GL, Butenhoff JL Jr, Olsen GW, et al. The toxicology of perfluo- rooctanoate. Crit Rev Toxicol. 2004;34: 351-384.
2. Lau C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. Perfluoroal- kyl acids: a review of monitoring and toxicological findings. Toxicol Sci. 2007; 99:366-394.
3. Butenhoff JL, Kennedy GL, Frame SR, O'Connor JC, York RG. The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. Toxicology. 2004;196:95-116.
4. Lau C, Thibodeaux JR, Hanson RG, et al. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol Sci. 2006;90:510-518.
5. Abbott BD, Wolf CJ, Schmid JE, et al. Perfluorooctanoic acid (PFOA)-induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha (PPARa). Toxicol Sci. 2007;98:571-581.
6. Sibinski LJ, Allen JL, Erickson EE. Two Year Oral (diet) Toxicity/Carcinogenicity Study of Fluorochemical FC-143 in Rats. St. Paul, MN: Riker Laboratories, Inc., Expt. No. 0281CR0012. U.S. Environmental Protection Agency Administrative Record 226-0437-0440; 1987.
7. Cook JC, Murray SM, Frame SR, et al. Induction of Leydig cell adenomas by ammonium perfluorooctanate: a possible endocrine related mechanism. Toxicol Appl Pharmacol. 1992;192:209-217.
8. Biegel LB, Hurtt ME, Frame SR, O'Connor JC, Cook JC. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci. 2001;60:44-55.
9. Maloney EK, Waxman DJ. Transactiva-tion of PPARαa and PPARγ by structurally diverse environmental chemicals. Toxicol Appl Pharmacol. 1999;161:209- 218.
10. Butenhoff JL, Gaylor DW, Moore JA, et al. Characterization of risk for general population exposure to perfluorooctano- ate. Regul Toxicol Pharmacol. 2004;39: 363-380.
11. Andersen ME, Clewell HJ, Tan YM, Butenhoff JL, Olsen GW. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys probing the determinants of long plasma half- lives. Toxicology. 2006;227:156-164.
12. Klaunig JE, Babich MA, Baetcke KP, et al. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol. 2003; 33:655-780.
13. Palmer CN, Hsu M-H, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol. 1998;53:14-22.
14. Cheung C, Akiyama TE, Ward JM, et al. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated re ceptor alpha. Cancer Res. 2004;64: 3849-3854.
15. Morimura K, Cheung C, Ward JM, Redd JK, Gonzalez FJ. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis. 2006;27:1074-1080.
16. Rosen MB, Lee JS, Ren H, et al. Toxi-cogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPARalpha and CAR. Toxicol Sci. 2008;103:46-56.
17. Kudo N, Kawashima Y. Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J Toxicol Sci. 2003;28:49-57.
18. Butenhoff J, Costa G, Elcombe C, et al. Toxicity of ammonium perfluorooctano-ate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol Sci. 2002;69:244-257.
19. Harada K, Inoue K, Morikawa A, Yoshi- naga T, Saito N, Koizumiet A. Renal clearance of perfluorooctane sulfonate and perfluorooctanoate in humans and their species-specific excretion. Environ Res. 2005;99:253-261.
20. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of per- fluorooctanesulfonate, perfluorohexane- sulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;1 15: 1298-1305.
21. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL. Serum concentrations of 11 polyfluoroalkyl compounds in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 1999- 2000. Environ Sci Technol. 2007;41: 2237-2242.
22. Emmett EA, Shofer FS, Zhang H, Freeman D, Desai C, Shaw LM. Community exposure to perfluorooctanoate: relationships between serum concentrations and exposure sources. / Occup Environ Med. 2006;48:759-770.
23. Kannan K, Corsolini S, Falandysz J, et al. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol. 2004;38:4489-4495.
24. Olsen GW, Huang H-Y, Helzlsouer KJ, Hansen KJ, Butenhoff JL, Mandel JH. Historical comparison of perfluorooctanesulfonate, perfluorooctanoate, and other fluorochemicals in human blood. Environ Health Perspect. 2005; 113:539-545.
25. Giesy JP, Kannan K. Global distribution of perfluorooctane sulfonate and related perfluorinated compounds in wildlife. Environ Sci Technol. 2001;35:1339- 1342.
26. Nakata H, Kannan K, Nasu T, Cho H-S, Sinclair E, Takemura A. Perfluorinated contaminants in sediment and aquatic organisms collected from shallow water and tidal flat areas of the Ariake Sea, Japan: environmental fate of perfluorooctane sulfonate in aquatic ecosystems. Environ Sci Technol. 2006;40:4916- 4921.
27. Tao L, Kannan K, Kajiwara N, et al. Perfluorooctanesulfonate and related fluorochemicals in albatrosses, elephant seals, penguins, and polar skuas from the Southern Ocean. Environ Sci Technol. 2006;40:7642-7648.
28. US Environmental Protection Agency. Perfluorooctanoic Acid. 2008. Available at: http://www.epa.gov/oppt/pfoa. Accessed October 3, 2008.
29. UK Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. Second Draft Working Paper on the Tolerable Daily Intake for Perfluorooctanoic Acid. 2006. Available at: http://cot.gov.uk/pdfs/tox-2006- 18.pdf. Accessed October 3, 2008.
30. Ubel FA, Sorenson SD, Roach DE. Health status of plant workers exposed to fluorochemicalsa preliminary report. Am Ind Hyg Assoc J. 1980;41:584-589.
31. Gilliland FD, Mandel JS. Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med. 1993;35:950-954.
32. Alexander BH. Mortality Study of Workers Employed at the 3M Cottage Grove Facility. St. Paul, MN: 3M Company; Washington DC: U.S. EPA Public Docket AR-226-1030a018; 2001.
33. Leonard RC, Kreckmann KH, Sakr CJ, Symons JM. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann Epidemiol. 2008;18:15-22.
34. Alexander BH, Olsen GW. Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. Ann Epidemiol. 2007;17:471-478.
35. Gilliland FD, Mandel JS. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins and cholesterol: a study of occupationally exposed men. Am J Ind Med. 1996;29:560-568.
36. Olsen GW, Gilliland FD, Burlew MM, Burris JM, Mandel JS, Mandel JHL. An epidemiologic investigation of reproductive hormones in men with occupational exposure to pefluorooctanoic acid. J Occup Environ Med. 1998;40:614-621.
37. 37.Olsen GW, Burris JM, Burlew MM, Mandel JH. Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctansulfon- ate production workers. Drug Chem Toxicol. 2000;23:603-620.
38. Olsen GW, Burris JM, Burlew MM, Mandel JH. Epidemiologic assessment of workers serum perfluorooctansulfonate (PFOS) and pefluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med. 2003;45:260-270.
39. Olsen GW, Zobel LR. Assessment of lipid, hepatic, and thyroid parameters with serum perfluooctanoate (PFOA) concentrations in fluochemical production workers. Int Arch Occup Environ Health. 2007;81:231-246.
40. Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. Longitudinal study of serum lipids and liver enzymes in worker with occupational exposure to ammonium perfluooctanoate. J Occup Environ Med. 2007;49:872-879.
41. Sakr CJ, Kreckmann KH, Green JW. Gilles PJ, Reynolds JL, Leonard RC. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluooctanoate or APFO) as part of genera) health survey in a cohort of occupationally exposed workers. J Occup Environ Med. 2007;49: 1086-1096.
42. Hansen KJ, Clemen LA, Ellefson ME, Johnson JHO. Compound-specific, quantitative characterization of organic fluoro- chemicals in biological matrices. Environ Sci Technol. 2001;35:766-770.
43. Twisk JWR. Applied Longitudinal Data Analysis for Epidemiology. Cambridge: Cambridge University Press; 2003.
44. StataCorp. Stata Statistical Software: Release 10. College Station. TX: StataCorp LP; 2007.
45. Xie Y, Yang Q, Nelson BD, DePierre JW. The relationship between liver peroxisome proliferation and adipose tissue atrophy induced by peroxisome prolifera- tor exposure and withdrawal in mice. Biochem Pharmacol. 2003;66:749-756.
46. Michalik L, Desvergne B, Dreyer C, DeGavillet M, Laurini RN, Wahl W. PPAR expression and function during vertebrate development. Int J Dev Biol. 2002;46:105-114.
47. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and growth. J Biol Chem. 2001; 276:37731-37734.
48. Toth B, Hornung D, Scholz C, Djalali S, Friese K, Jeschke U. Peroxisome prolif- eratoractivated receptors: new players in the field of reproduction. Am J Reprod Immunol. 2007;58:289-310.
49. Katakura M, Kudo N, Tsuda T, Hibino Y, Mitsumoto A, Kawashima Y. Rat organic anion transporter 3 and organic anion transporting polypeptide 1 mediate per- fluorooctanoic acid transport. J Health Sci. 2007;53:77-83.
50. Kudo N, Katakura M, Sato Y, Kawashima Y. Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem Biol Interact. 2002;139:301-316.
51. Pons N, Pipino S, De Matteis F. Interaction of polyhalogenated compounds of appropriate configuration with mammalian or bacterial CYP enzymes. Increased bilirubin and uropofobylinogen oxidation. Biochem Pharmacol. 2003;66:405-414.
52. Karlsson B, Knutsson A, Lindahl B, Alfredsson L. Metabolic disturbances in male workers with rotating three-shift work. Results of the WOLF study. Int Arch Occup Environ Health. 2003; 76:424-430.
53. Biggi N, Consonni D, Galluzzo V, Sogli- ani M, Costa G. Metabolic syndrome in permanent nightworkers. Chronohiol Int. 2008;25:1-12.